An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
Abstract Background Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, there is few inflammation based cumulative prognostic score system for pati...
Main Authors: | Feifei Sun, Jia Zhu, Suying Lu, Zijun Zhen, Juan Wang, Junting Huang, Zonghui Ding, Musheng Zeng, Xiaofei Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-017-3931-z |
Similar Items
-
The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01) -
The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01) -
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
by: Min Ji Jeon, et al.
Published: (2023-11-01) -
Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study
by: David Belada, et al.
Published: (2007-01-01) -
Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
by: Hyehyun Jeong, et al.
Published: (2022-05-01)